Literature DB >> 21146665

Growth differentiation factor 15--an early marker of abnormal function of the Fontan circuit in patients with univentricular hearts.

Tanja M Raedle-Hurst1, Karsten Koenigstein, Frank Gruenhage, Jochen Raedle, Eva Herrmann, Hashim Abdul-Khaliq.   

Abstract

BACKGROUND: In patients after the Fontan procedure, assessment of ventricular function is difficult and amino-terminal pro-B-type natriuretic peptide levels failed to be directly related to echocardiographic measures of systolic ventricular function. The aim of the study was to evaluate growth differentiation factor 15 (GDF-15), a marker of various stress pathways in the heart and extracardiac tissues.
METHODS: Plasma GDF-15 levels were measured in 38 consecutive patients after the Fontan procedure and compared to clinical, echocardiographic, and laboratory data; liver tissue stiffness; and venous hepatic flow velocities.
RESULTS: Mean GDF-15 levels were 987.2±440.5 pg/mL in patients with an ejection fraction (EF)<50% as compared to 520.2±143.1 pg/mL in those with an EF≥50% (P<.001). Growth differentiation factor 15 levels were significantly related to the EF of the single ventricle (r=-0.66, P<.001), New York Heart Association functional class (r=0.43, P=.008), and γGT levels (r=0.50, P=.002) but weakly to liver tissue stiffness. According to receiver operating characteristic curve analysis, an EF<50% was best predicted by GDF-15 levels (area under the curve [AUC] 0.90, P<.001), peak venous hepatic flow at deep inspiration (AUC 0.89, P=.002), and age at Fontan operation (AUC 0.86, P=.001). Growth differentiation factor 15 and age at Fontan operation proved to be independent predictors in the multivariate analysis. The optimal cutoff of GDF-15 for the prediction of an EF<50% was calculated to be 613 pg/mL with a sensitivity of 90.0% and specificity of 85.7%.
CONCLUSIONS: Growth differentiation factor 15 might be helpful in detecting early abnormal function of the Fontan circuit in patients with univentricular hearts. In patients with GDF-15 levels exceeding 613 pg/mL, further cardiac evaluation should be considered because impaired systolic function of the single ventricle may be present.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146665     DOI: 10.1016/j.ahj.2010.08.033

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Plasma Growth Differentiation Factor-15 is a Potential Biomarker for Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.

Authors:  Gang Li; Yan Li; Xiao-Qiu Tan; Peng Jia; Jian Zhao; Dong Liu; Ting Wang; Bin Liu
Journal:  Pediatr Cardiol       Date:  2017-08-18       Impact factor: 1.655

2.  Physical Activity in Fontan Patients Relates to Quality of Life and Sleep Quality.

Authors:  Alessia Callegari; Kathrin Faeth; Charlène Pfammatter; Ruedi Jung; Florian Berger; Barbara Burkhardt; Emanuela R Valsangiacomo Buechel
Journal:  Front Cardiovasc Med       Date:  2022-06-14

Review 3.  Cardiac biomarkers in pediatric heart disease: A state of art review.

Authors:  Benedict A Fernandes; Kevin O Maher; Shriprasad R Deshpande
Journal:  World J Cardiol       Date:  2016-12-26

4.  GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation.

Authors:  Sophie L Meyer; Djoeke Wolff; Floris-Jan S Ridderbos; Graziella Eshuis; Hans Hillege; Tineke P Willems; Tjark Ebels; Joost P van Melle; Rolf M F Berger
Journal:  J Am Heart Assoc       Date:  2020-05-08       Impact factor: 5.501

5.  Associations Between Blood Biomarkers, Cardiac Function, and Adverse Outcome in a Young Fontan Cohort.

Authors:  Eva van den Bosch; Sjoerd S M Bossers; Vivian P Kamphuis; Eric Boersma; Jolien W Roos-Hesselink; Johannes M P J Breur; Arend D J Ten Harkel; Livia Kapusta; Beatrijs Bartelds; Arno A W Roest; Irene M Kuipers; Nico A Blom; Laurens P Koopman; Willem A Helbing
Journal:  J Am Heart Assoc       Date:  2021-02-24       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.